Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis

Fraser HM, Hamish M. Fraser, H. M. Fraser, Jürgen Sandow, Sandow J, J. Sandow, Cowen GM, G M Cowen, Lumsden MA, M A Lumsden, Mary Ann Lumsden, R. E. B. Haining, R Haining, Haining R, S. K. Smith, Smith SK
Fertility and sterility · 1990 · vol. 53(1) , pp. 61–68 · doi:10.1016/s0015-0282(16)53217-8 · PMID:2104808 · W2411434448
article OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This study investigated the long-term efficacy of a GnRH agonist implant for suppressing ovarian function in endometriosis patients and found it effectively reduced symptoms and hormone levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Ten endometriosis patients received luteinizing hormone releasing hormone (LH-RH) agonist (buserelin) implant injections (6.6 mg subcutaneously) at days 0, 42, 84 and 126. Serum LH and follicle-stimulating hormone (FSH) were lowered by day 14. Luteinizing hormone remained at basal concentrations while FSH returned to values in the low-normal range of the menstrual cycle by day 35. At the end of the luteal phase during which treatment commenced, estrone and pregnanediol declined and remained at postmenopausal or early follicular phase values until days 305 to 460. Time to first ovulation ranged from 321 to 481 days after starting treatment. After the initial menstruation, only three instances of bleeding occurred during treatment. Pelvic pain was relieved or markedly reduced by day 42 and remained absent throughout the period of ovarian suppression. These results indicate the potential of a long-acting LH-RH agonist implant to form the basis for the treatment of symptomatic endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Gonadotropin-Releasing Hormone Ovary Administration, Intranasal Adult Buserelin Buserelin Buserelin Dose-Response Relationship, Drug Drug Implants Endometriosis Female Gonadotropin-Releasing Hormone Humans Injections, Subcutaneous Menstruation Menstruation Menstruation Ovarian Follicle

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (10)

Source provenance

europepmc
last seen: 2026-09-03T06:15:13.668130+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:15.619952+00:00
unpaywall
last seen: 2026-09-03T06:36:50.994332+00:00
License: CC0 · commercial use OK